Skip to main content

Here's why Gland Pharma IPO premium fell significantly in grey market

Gland Pharma aims to raise Rs 6,479.54 crore via public issue, of which Rs 1,943.86 crore has already been raised from anchor investors on November 6.

Gland Pharma is set to open its initial public offering for subscription on November 9, but its premium in the grey market fell significantly after the announcement of issue price band at Rs 1,490-1,500 per share.

The grey market premium dropped to around Rs 50-70 against around Rs 200 quoted before the company fixed IPO price band, sources told Moneycontrol.

The fall is largely attributed to the pricing of issue which is comparatively on the higher side and also higher than market expectations given the 80 percent rally registered by the pharma index from March lows, experts feel.

In fact, the pharma was the second-highest gainer among sectors in the last 9 months, while the equity benchmark indices rallied 60 percent in same period and are near record high levels.



"Gland Pharma is coming up with the IPO at PE levels of 30.1x for FY20 which is slightly premium to midcap pharma peers along with this company also trading at EV/Sales of 8.1x and EV/EBITDA of 20.1x for FY2020 which are also expensive to peers. Price band fixed by the company is above market expectations as per market news," Yash Gupta - Equity Research Associate at Angel Broking told Moneycontrol.

Pharma index has given a good run-up throughout this year, hence at this point of time the pharma index is consolidating and other sectors have taken the lead, he said.

Gaurav Garg, Head of Research at CapitalVia Global Research feels the market was expecting a price band at around Rs 1,300 per share, which may be the reason for the fall-off premium on the grey market.

Gland Pharma is largely owned by the Chinese companies Fosun Singapore and Shanghai Fosun Pharma with 74 percent stake pre-offer, which could be one of the reasons for the decline in premium, given the clashes between India and China at border, experts feel.

"At a time when border tensions are heating up, the business is largely purchased by the Chinese company and 3.87 percent of the stake is held by 10 companies belonging to Ramalinga Raju's and the family involved in the Satyam scam," Gaurav Garg said.

Gland Pharma will launch its maiden public offer on November 9, which consists a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoters and others.

Promoters Fosun Pharma Industrial Pte and Gland Celsus Bio Chemicals will sell over 1.9 crore shares and 1 crore shares via offer for sale respectively, while Empower Discretionary Trust will offload 35,73,014 equity shares and Nilay Discretionary Trust 18,74,500 equity shares.

The issue will close on November 11. The company aims to raise Rs 6,479.54 crore via public issue, of which Rs 1,943.86 crore has already been raised from anchor investors on November 6.

The company will utilise the net fresh issue proceeds towards funding incremental working capital requirements, funding capital expenditure requirements and general corporate purposes

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more